Moderna, Inc. (MRNA) FY2024 Annual P&L / Income Statement

Moderna, Inc. (MRNA) FY2024 Annual P&L / Income Statement

Income statement for 2024-01-01 through 2024-12-31. View: Product and service (Narrative). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenue

3,236,000,000 US dollars

Cost of sales

1,464,000,000 US dollars

Gross profit (calculated)

1,772,000,000 US dollars

Operating expenses (calculated)

5,717,000,000 US dollars

(Loss) income from operations

negative 3,945,000,000 US dollars

Other income (expense), net (calculated)

338,000,000 US dollars

(Loss) income before income taxes

negative 3,607,000,000 US dollars

(Benefit from) provision for income taxes

negative 46,000,000 US dollars

Net (loss) income

negative 3,561,000,000 US dollars

Licensing and royalty revenue

42,000,000 US dollars

Other revenue

127,000,000 US dollars

Grant revenue

37,000,000 US dollars

Undisclosed (calculated)

3,030,000,000 US dollars

Research and development

4,543,000,000 US dollars

Selling, general and administrative

1,174,000,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.